Patents Examined by Kamal A. Gaeed
  • Patent number: 7384962
    Abstract: The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: June 10, 2008
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Balasubramanian Gopalan, Laxmikant Atmaram Gharat, Aftab Dawoodbhai Lakdawala, Usha Karunakaran
  • Patent number: 7368465
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: May 6, 2008
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Patent number: 7365087
    Abstract: This invention provides compounds of the formula: wherein A?, X and Y are defined in the specification. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 29, 2008
    Assignee: Wyeth
    Inventors: Phaik-Eng Sum, David Brian How, Darrin William Hopper, Matthew Douglas Vera, Joshua James Sabatini
  • Patent number: 7241787
    Abstract: The invention relates to substituted N-cyclohexylheterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof, to processes for their preparation and to their use as medicaments. Compounds of the formula I, in which the radicals have the stated meanings, and the physiologically tolerated salts thereof, and process for their preparation are described. The compounds bring about for example a weight reduction in mammals and are suitable for example for the prevention and treatment of obesity and diabetes.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: July 10, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Lothar Schwink, Thomas Boehme, Matthias Gossel, Siegfried Stengelin
  • Patent number: 7217701
    Abstract: An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I). The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: May 15, 2007
    Assignee: Katsuhiko Mikoshiba
    Inventors: Katsuhiko Mikoshiba, Hirohide Iwasaki, Takayuki Maruyama, Shin-ichi Hamano